Merus NV Receives a Buy from Jefferies

By Ryan Adsit

Jefferies analyst Brian Abrahams reiterated a Buy rating on Merus NV (NASDAQ: MRUS) yesterday and set a price target of $21. The company’s shares closed yesterday at $15.25.

Abrahams noted:

“MRUS’s bispecifics continue to move along, with ’17 setting up for an initial glimpse followed by more complete data that should help define 128’s profile in solid tumors, initial data that could validate ‘117’s differentiated mech. in heme maligancies, and advancement of the remaining pipeline programs. We continue to see appreciation potential based on the promise of MRUS’s programs and high-quality bispecifics platform.”

According to, Abrahams is a 1-star analyst with an average return of -2.5% and a 41.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as DBV Technologies S.A. – American, Achillion Pharmaceuticals, and Protalix Biotherapeutics.

Merus NV has an analyst consensus of Moderate Buy.

The company has a one year high of $19.63 and a one year low of $7.26. Currently, Merus NV has an average volume of 7,808.

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.